Exdensur evaluation in New York

Review the new twice-yearly depemokimab-ulaa pathway with current-label, access, and provider-administration checks.

Exdensur was FDA approved on December 16, 2025 for add-on maintenance treatment of severe eosinophilic asthma in patients age 12 and older. Its every-six-month schedule is distinctive, but it does not remove the need for controller medicines, specialist oversight, authorization, patient-specific acquisition, administration-site confirmation, or follow-up.

Commercially listed does not mean available at Nao

DailyMed shows active U.S. package records, but Nao acquisition, payer contracting, specialty-pharmacy delivery, storage, and administration sites have not been publicly verified. Book an evaluation before arranging any shipment.

What the Exdensur evaluation confirms

The visit tests clinical fit and operational readiness separately. A six-month dose interval is not a reason to skip the diagnosis, current treatment, safety, or access review.

Labeled population

The current indication is add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and patients age 12 and older.

Asthma treatment history

The clinician reviews inhaled therapy, adherence and technique, exacerbations, systemic steroids, eosinophils, hospital care, and prior biologics.

Six-month continuity

The plan covers the next dose date, missed-dose handling, controller medicines, response checks, and what to do if asthma worsens between injections.

New-product access

The team verifies the benefit, authorization, specialty pharmacy or acquisition channel, patient cost, receiving clinic, storage, and provider administration.

What to expect from evaluation through follow-up

The order and timing depend on diagnosis, specialist responsibility, coverage, medication or infusion acquisition, the accepted care site, and clinical follow-up.

1. Confirm severe asthma

Bring pulmonary or allergy records, eosinophil results, lung testing, inhalers, steroid courses, exacerbation records, previous biologic history, and insurance.

2. Review the current label

The clinician checks age, eosinophilic phenotype, current controller treatment, hypersensitivity history, helminth risk, pregnancy considerations, and acute-care needs.

3. Verify product access

The care team confirms whether the plan covers Exdensur, the required documentation, acquisition or specialty pharmacy, patient cost, delivery address, and storage process.

4. Set administration and follow-up

Treatment is scheduled only after medication receipt and site approval. Follow-up tracks asthma control, adverse effects, controller use, and the next six-month dose.

Current Exdensur approval and label facts

The exact FDA-approved identity is Exdensur (depemokimab-ulaa). DailyMed's current label was revised in June 2026 and includes active U.S. package records.

Exdensur is an IL-5 antagonist approved for add-on maintenance treatment of severe eosinophilic asthma in patients age 12 and older.
The recommended dose is 100 mg by subcutaneous injection once every six months into the upper arm, thigh, or abdomen.
The current label says a healthcare provider should administer Exdensur. It is not a self-directed retail injection pathway.
Exdensur is not indicated for relief of acute bronchospasm or status asthmaticus. Existing controller and rescue plans remain essential.

Coverage, acquisition, and care-site planning

Nao can coordinate access steps after the clinical and receiving-site teams accept the plan. Coverage, assistance, medication availability, delivery timing, administration, and infusion access are never guaranteed.

Records and prescribing responsibility

The team confirms the diagnosis, current order, dose, responsible prescriber, monitoring plan, refill responsibility, adverse-event plan, and specialist follow-up.

Benefits and authorization

The care team reviews the pharmacy or medical benefit, required documentation, prior authorization, appeal options, expected patient cost, and eligible support resources.

Patient-specific acquisition

Medication is ordered or shipped only after the accepted acquisition channel, delivery address, receiving process, storage, and patient-specific appointment are confirmed.

Administration or infusion site

An evaluation clinic is not automatically a treatment site. The team confirms staff, equipment, emergency readiness, observation, and referral needs for the selected product.

Current product and operations status

Exdensur has an FDA approval date of December 16, 2025, a current June 2026 DailyMed label, active BLA status, and active package records. Local Nao acquisition and administration readiness remain release blockers.

Exdensur safety and continuity

Hypersensitivity reactions, including anaphylaxis, can occur. Stop treatment and begin appropriate care if a serious reaction occurs.
Do not abruptly discontinue inhaled or systemic corticosteroids when Exdensur begins. Any reduction must be gradual and supervised.
Treat a pre-existing helminth infection before treatment. Exdensur may be paused if an infection does not respond to therapy.
The label notes placental transfer and potentially prolonged infant exposure related to the molecule's YTE modification. Pregnancy decisions require an individual clinician discussion.

Review Nao Medical's urgent and emergency care guidance. Call 911 for a life-threatening emergency.

Clinics available for evaluation booking

The exact specialty route offers evaluation booking through the PCP NP visit type at these 11 clinics. Appointment times vary. The cards do not promise medication stock, same-day treatment, administration, infusion capability, or a product-specific receiving site. Those items are confirmed after evaluation.